Abstract: The present disclosure relates to systems and methods for providing individualized prognostic assessments of breast cancer recurrence (e.g., locoregional recurrence). The systems and methods involve measuring gene expression from a patient sample to create a gene expression signature which identifies subjects who are not likely to benefit from radiotherapy following breast cancer surgery.

Abstract: The present invention relates to methods, systems and kits for the diagnosis, prognosis and the determination of progression of cancer in a subject. The invention also provides biomarkers that define subgroups of prostate cancer, clinically useful classifiers for distinguishing prostate cancer subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping prostate cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping prostate cancer in a subject. Classifiers for subtyping a prostate cancer are provided. Methods of treating cancer based on molecular subtyping are also provided.

Abstract: Methods, systems, and kits for the diagnosis, prognosis, and treatment of breast cancer in a subject are disclosed. The invention also provides biomarkers and clinically useful classifiers for identifying subjects at low risk of breast cancer recurrence who may be spared from adjuvant chemotherapy and endocrine therapy. Further disclosed herein, in certain instances, are probe sets for use in detecting such biomarkers for determining the risk of breast cancer recurrence in a subject. Methods of treating breast cancer based on expression profiling to determine the risk of breast cancer recurrence are also provided.

Abstract: Methods, systems, and kits for the diagnosis, prognosis, and treatment of breast cancer in a subject are disclosed. The invention also provides biomarkers and clinically useful genomic classifiers for identifying subjects at low risk of breast cancer recurrence who are likely to benefit from adjuvant radiotherapy. Further disclosed herein, in certain instances, are probe sets for use in detecting such biomarkers for determining the risk of breast cancer recurrence in a subject (e.g., locoregional recurrence). Methods of treating breast cancer based on expression profiling to determine the risk of breast cancer recurrence are also provided.

Abstract: The present invention relates to methods, systems and kits for the diagnosis, prognosis and the determination of progression of cancer in a subject. The invention also provides biomarkers that define subgroups of prostate cancer, clinically useful classifiers for distinguishing prostate cancer subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping prostate cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping prostate cancer in a subject. Classifiers for subtyping a prostate cancer are provided. Methods of treating cancer based on molecular subtyping are also provided.

Abstract: Methods, compositions, and kits for identifying individuals who will be responsive to post-operative radiation therapy for treatment of prostate cancer are disclosed. In particular, the invention relates to a genomic signature based on expression levels of DNA Damage Repair genes that can be used to identify individuals likely to benefit from post-operative radiation therapy after a prostatectomy.